文献速递免疫规划传染病防控与疫情报告

大流行甲型H1N1pdm09流感疫苗诱导高水平流感特异性IgG和IgM抗体:酶免疫分析与双模式多重微阵列免疫分析法的比较

Pandemic influenza A(H1N1pdm09) vaccine induced high levels of influenza-specific IgG and IgM antibodies as analyzed by enzyme immunoassay and dual-mode multiplex microarray immunoassay methods.
PubMed 文献 · Vaccine · 2020-01-24

本研究以接种Pandemrix疫苗的成人血清(接种后第0、28、180天采集)为材料,建立可同时检测病毒特异性IgG和IgM抗体的多重微阵列免疫分析法(MAIA),并与传统酶免疫分析(EIA)和血凝抑制试验(HI)比较。MAIA与EIA在抗甲型流感IgG和IgM检测中相关性极好,与HI相关性良好。Pandemrix疫苗诱导抗H1N1pdm09抗体升高5–30倍(HI、EIA或MAIA检测),93–97%的接种者MAIA和EIA均显示病毒特异性IgG抗体明显升高,90–92%的接种者MAIA和EIA分别检出病毒特异性IgM抗体,55–62%的接种者IgM抗体持续至接种后6个月。

要点

  • MAIA与EIA检测抗甲型流感IgG和IgM抗体相关性极好,与HI相关性良好。
  • Pandemrix疫苗诱导抗H1N1pdm09抗体升高5–30倍(HI、EIA或MAIA检测)。
  • 93–97%接种者MAIA和EIA均显示病毒特异性IgG抗体明显升高,90–92%分别检出IgM抗体。

核心结论

  • 大流行流感疫苗诱导强抗甲型流感IgG和IgM应答,并持续数月。
  • MAIA是同时检测针对多种病毒抗原的抗病毒IgG和IgM抗体的优良方法,适合大规模流行病学和疫苗免疫研究。

研究设计与样本

  • 以接种Pandemrix疫苗的成人血清为研究材料,采集接种后第0、28和180天血清。
  • 建立新型多重微阵列免疫分析法(MAIA),同时检测病毒特异性IgG和IgM抗体,并与传统酶免疫分析(EIA)和血凝抑制试验(HI)比较。

主要发现

  • MAIA与EIA检测抗甲型流感IgG和IgM抗体相关性极好,与HI相关性良好。
  • Pandemrix疫苗诱导抗H1N1pdm09流感抗体升高5–30倍(HI、EIA或MAIA检测)。
  • 93–97%的接种者MAIA和EIA均显示病毒特异性IgG抗体明显升高。
  • 90–92%的接种者MAIA和EIA分别检出病毒特异性IgM抗体。
  • 55–62%的接种者IgM抗体持续至接种后6个月。

临床怎么用

  • 作者认为MAIA适合大规模流行病学和疫苗免疫研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Influenza A viruses continue to circulate throughout the world as yearly epidemics or occasional pandemics. Influenza infections can be prevented by seasonal multivalent or monovalent pandemic vaccines. In the present study, we describe a novel multiplex microarray immunoassay (MAIA) for simultaneous measurement of virus-specific IgG and IgM antibodies using Pandemrix-vaccinated adult sera collected at day 0 and 28 and 180 days after vaccination as the study material. MAIA showed excellent correlation with a conventional enzyme immunoassay (EIA) in both IgG and IgM anti-influenza A antibodies and good correlation with hemagglutination inhibition (HI) test. Pandemrix vaccine induced 5-30 fold increases in anti-H1N1pdm09 influenza antibodies as measured by HI, EIA or MAIA. A clear increase in virus-specific IgG antibodies was found in 93-97% of vaccinees by MAIA and EIA. Virus-specific IgM antibodies were found in 90-92% of vaccinees by MAIA and EIA, respectively and IgM antibodies persisted for up to 6 months after vaccination in 55-62% of the vaccinees. Pandemic influenza vaccine induced strong anti-influenza A IgG and IgM responses that persisted several months after vaccination. MAIA was demonstrated to be an excellent method for simultaneous measurement of antiviral IgG and IgM antibodies against multiple virus antigens. Thus the method is well suitable for large scale epidemiological and vaccine immunity studies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kazakova A, Kakkola L, Ziegler T, et al. Pandemic influenza A(H1N1pdm09) vaccine induced high levels of influenza-specific IgG and IgM antibodies as analyzed by enzyme immunoassay and dual-mode multiplex microarray immunoassay methods. Vaccine. 2020. PMID: 31987689. doi:10.1016/j.vaccine.2020.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。